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ABSTRACT 28 
The growing demand for efficient chemotherapy in many cancers requires novel approaches in 29 
target-delivery technologies. Nanomaterials with pH-responsive behavior appear to have 30 
potential ability to selectively release the encapsulated molecules by sensing the acidic tumor 31 
microenvironment or the low pH found in endosomes. Likewise, polyethylene glycol (PEG)- 32 
and poloxamer-modified nanocarriers have been gaining attention regarding their potential to 33 
improve the effectiveness of cancer therapy. In this context, DOX-loaded pH-responsive 34 
nanoparticles (NPs) modified with PEG or poloxamer were prepared and the effects of these 35 
modifiers were evaluated on the overall characteristics of these nanostructures. Chitosan and 36 
tripolyphosphate were selected to form NPs by the interaction of oppositely charged 37 
compounds. A pH-sensitive lysine-based amphiphile (77KS) was used as a bioactive adjuvant. 38 
The strong dependence of 77KS ionization with pH makes this compound an interesting 39 
candidate to be used for the design of pH-sensitive devices. The physicochemical 40 
characterization of all NPs has been performed, and it was shown that the presence of 77KS 41 
clearly promotes a pH-triggered DOX release. Accelerated and continuous release patterns of 42 
DOX from CS-NPs under acidic conditions were observed regardless of the presence of PEG 43 
or poloxamer. Moreover, photodegradation studies have indicated that the lyophilization of NPs 44 
improved DOX stability under UVA radiation. Finally, cytotoxicity experiments have shown 45 
the ability of DOX-loaded CS-NPs to kill HeLa tumor cells. Hence, the overall results suggest 46 
that these pH-responsive CS-NPs are highly potent delivery systems to target tumor and 47 
intracellular environments, rendering them promising DOX carrier systems for cancer therapy. 48 
Keywords: chitosan nanoparticles; doxorubicin; in vitro release; in vitro cytotoxicity; lysine-49 
based surfactant; pH-sensitivity 50 
1. Introduction 51 
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Doxorubicin (DOX) is an anthracycline antibiotic commonly used as a chemotherapeutic agent 52 
[1]. Due to its broad-spectrum of antitumor activity, it has been incorporated into several nano-53 
sized materials, including pH-responsive microgels [2], temperature-responsive micelles [3], 54 
liposomes [4] and polymeric nanoparticles (NPs) [5,6]. DOX antineoplastic effects can occur 55 
by different mechanisms, such as free radical generation, which is well associated with the 56 
cardiotoxicity of anthracyclines [7]. Drug delivery systems have been gaining attention in recent 57 
years as a promising approach to improve cancer treatment and prevent toxicity in healthy 58 
tissues. It is noteworthy that by adding different modifiers, these systems can be designed for 59 
cancer cell-specific targeting as well as for biological, chemical, or physical stimulus response 60 
[8,9]. 61 
 Considering that endosomal pH (~ 6.5 to 5.5) [10] and the tumor extracellular pH (pHe 62 
~ 6.6) are notably lower than those of normal tissue (pH ~ 7.4) [11], pH-sensitive devices have 63 
been widely researched as drug delivery strategies for cancerous diseases [9]. In this context, 64 
our group has paid special attention to a bioactive amino acid-based surfactant derived from 65 
Nα,Nε-dioctanoyl lysine with an inorganic sodium counterion (77KS), which in previous studies 66 
shown pH-responsive properties and low cytotoxicity [12-14]. Therefore, here we selected 67 
77KS as an adjuvant with potential ability to promote the pH-triggered DOX release in the 68 
tumor microenvironment and endosomal compartments (Fig. 1). 69 
 Chitosan (CS) is a nontoxic, biocompatible and biodegradable polymer that has been 70 
emerging as one of the most promising delivery vehicles for cancer chemotherapy [15]. 71 
Chitosan has been widely used for the development of DOX-loaded NPs by simple and mild 72 
preparation techniques [5,16-18]. CS-NPs modified by polyethylene glycol (PEG) are explored 73 
due to the ability of this hydrophilic polymer to prolong the circulation time of nanocarriers in 74 
the blood stream. This mechanism allows NP accumulation in the tumor region via enhanced 75 
permeability and retention (EPR) effect, which, in turn, increases tumor exposure to the 76 
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encapsulated drug [19-22]. Likewise, Pluronic block copolymers (or non-proprietary name 77 
“poloxamer”) have been studied as biological response modifiers. They are amphiphilic 78 
synthetic polymers with tumor-sensitizing activity in multidrug resistant (MDR) cells, which is 79 
especially attributed to the inhibition of P-glycoprotein [23]. For this reason, it has been reported 80 
that the association of DOX to poloxamer-based formulations potentiates the drug activity 81 
against non-MDR and, especially, MDR tumor cells [24-26]. 82 
 Therefore, the aim of the present study was to prepare PEGylated and poloxamer-83 
modified CS-NPs incorporating a lysine-based surfactant as a pH-responsive bioactive adjuvant. 84 
The NPs were well characterized and the mathematical modeling of pH-triggered DOX release 85 
profiles was discussed. NP suspensions and lyophilized samples were analyzed regarding their 86 
stability at low temperature and under UVA radiation. Finally, in order to gain preliminary 87 
insights into the role of the modifiers on the antitumor activity of NPs, the cytotoxicity of free 88 
and entrapped drug was assessed by an in vitro cell-based assay.  89 
2. Materials and methods 90 
2.1. Materials 91 
Chitosan (CS) of low molecular weight (deacetylation degree, 75-85%; viscosity, 20-300 cP 92 
according to the data sheet of the manufacturer), pentasodium tripolyphosphate (TPP), 93 
polyethylene glycol methyl ether (mPEG, Mn = 5,000), poloxamer 188 solution (10%, w/v) and 94 
2,5-diphenyl-3,-(4,5-dimethyl-2-thiazolyl) and tetrazolium bromide (MTT) were purchased 95 
from Sigma-Aldrich (St. Louis, MO, USA). Reagents for cell culture were from Vitrocell 96 
(Campinas, SP, Brazil). Doxorubicin (DOX, state purity 98.32%) was obtained from Zibo 97 
Ocean International Trade (Zibo, Shangdong, P.R., China). Acetonitrile and glacial acetic acid 98 
were purchased from Tedia (Fairfield, USA). All other solvents and reagents were of analytical 99 
grade.  100 
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2.2. Surfactant included in the nanoparticles 101 
An anionic amino acid-based surfactant derived from Nα,Nε-dioctanoyl lysine and with an 102 
inorganic sodium counterion (77KS) was included in the NP formulation. The surfactant 103 
chemical structure is formed by two alkyl chains (each with eight carbon atoms) bound to the 104 
amino acid lysine. It has a molecular weight of 421.5 g/mol and a critical micellar concentration 105 
(CMC) of 3 x 103 µg/ml [27,28]. This surfactant was synthesized as described elsewhere [29]. 106 
2.3. Preparation of nanoparticles 107 
CS-NPs were spontaneously formed by ionotropic gelation process, according to the 108 
methodology first described by Calvo et al. [30]. DOX stock solution was prepared in ultrapure 109 
water in order to give a final concentration of 2.0 mg/ml. Chitosan at 1.0 mg/ml was dissolved 110 
in a 1.0% (v/v) acetic acid aqueous solution under magnetic stirring for 2 h, and pH was adjusted 111 
to 5.5 with 10 M NaOH [31]. A mixed solution of the cross-linker TPP and the surfactant 77KS 112 
was prepared in ultra-pure water at 2.0 mg/ml and 0.5 mg/ml, respectively. Initially, DOX stock 113 
solution was added to 5 ml of CS solution (CS:DOX ratio 5:0.5, w/w) and maintained under 114 
magnetic stirring (1000 rpm) for 10 min. Then, 1 ml of a premixed TPP:77KS solution (ratio 115 
equal 2:0.5, w/w) was added drop-wise into the CS:DOX solution. NPs (DOX-CS-NPs) were 116 
formed spontaneously and the gelation process was carried out under constant magnetic stirring 117 
for 20 min at room temperature.  118 
In order to obtain PEGylated DOX-CS-NPs (PEG-DOX-CS-NPs), a mixed solution of 119 
CS and PEG (at 1 mg/ml and 10 mg/ml, respectively) was prepared in 1.0% (v/v) acetic acid. 120 
To 5 ml of this solution, DOX stock solution was added and stirred for 10 min (CS:PEG:DOX 121 
ratio 5:50:0.5, w/w/w). Afterwards, 1 ml of TPP:77KS (2:0.5, w/w) was added drop-wise and 122 
stirred for 20 min. 123 
6 
 
Poloxamer-modified DOX-CS-NPs (Polox-DOX-CS-NPs) were obtained by adding 124 
0.5% (w/v) of poloxamer to 5 ml of a 1 mg/ml CS solution. Next, DOX stock solution was 125 
added to give a final ratio of CS:Poloxamer:DOX 5:25:0.5 (w/w/w). Finally, 1 ml of TPP:77KS 126 
(2:0.5, w/w) was added drop-wise under vigorous magnetic stirring for 20 min.  127 
Unloaded NPs were prepared similarly for each formulation, thus omitting the drug. All 128 
procedures involving DOX were conducted in a low incidence of light. The resulting DOX-129 
loaded NPs were purified by dialysis for 1 h in distilled water (dialysis bag - Sigma-Aldrich, 130 
14,000 MWCO), in order to remove the non-encapsulated drug and non-incorporated 131 
constituents. 132 
2.4. Characterization of nanoparticles 133 
The mean hydrodynamic diameter and the polydispersity index (PDI) of the NPs were 134 
determined by dynamic light scattering (DLS) using a Malvern Zetasizer ZS (Malvern 135 
Instruments, Malvern, UK), without any dilution of the samples. The zeta potential (ZP) values 136 
of the NPs were assessed by determining electrophoretic mobility using the same equipment 137 
after dilution of the formulations in 10 mM NaCl aqueous solution (1:10 volume per volume). 138 
Each measurement was performed using at least three sets of ten runs at 25°C. The pH 139 
measurements were verified directly in the NP suspensions, using a calibrated potentiometer 140 
(UB-10; Denver Instrument, Bohemia, NY, USA), at room temperature. Finally, the spectral 141 
properties of the drug were assessed before its encapsulation and also after extraction from the 142 
NP structure. This assay was performed in order to verify the stability of DOX after entrapment 143 
into the NP matrix. Experiments were performed on a double-beam UV-Vis spectrophotometer 144 
(Shimadzu, Japan) model UV–1800, with a fixed slit width (2 nm) and a 10 mm quartz cell was 145 
used to obtain spectrum and absorbance measurements. The diluent optimized was water pH 146 
3.0, acidified with glacial acetic acid. 147 
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2.5. Drug encapsulation efficiency  148 
The quantitative analyses were performed by a reversed-phase liquid chromatography (RP-LC) 149 
method that was previously validated according to international guidelines and proved to be 150 
specific, linear, precise, accurate and robust (unpublished data). Chromatographic analyses were 151 
carried out on a LC 1260 Agilent Technologies system (Agilent Technologies, Santa Clara, CA, 152 
USA), using a Waters XBridgeTM C18 column (250 mm x 4.6 mm I.D., 5μm), with a mobile 153 
phase consisting of 90% (v/v) acetonitrile in water and water pH 3.0, acidified with glacial acetic 154 
acid (33:67, v/v) and UV detection set at 254 nm. Data analysis was performed with EZChrom 155 
software program (version A.01.05). Total drug content was achieved by dilution of the NP 156 
suspensions in methanol (1:1, v/v) followed by sonication for 15 min, which allowed total drug 157 
extraction from the NP matrix. The resulting solution was diluted to the suitable concentration 158 
and analyzed by RP-LC. The drug association efficiency was determined by 159 
ultrafiltration/centrifugation technique using Amicon Ultra-0.5 Centrifugal Filters (10,000 Da 160 
MWCO, Millipore). An amount of the non-purified NP suspension was placed into this device 161 
and submitted to 10,000 rpm for 20 min in a Sigma 2-16P Centrifuge (Sigma, Germany). The 162 
encapsulation efficiency (EE%) was calculated as the difference between total and free DOX 163 
concentrations determined in the NP suspension (total drug content) and in the ultrafiltrate, 164 
respectively, using the mentioned analytical method. 165 
2.6. pH-dependent in vitro DOX release  166 
In vitro release assessments of DOX from the different CS-NPs were performed using the 167 
dialysis method. An aliquot of the NPs (1 ml) was placed into a dialysis bag (Sigma-Aldrich, 168 
14,000 MWCO), which was immersed in 50 ml of phosphate buffered saline (PBS) at 37ºC and 169 
kept under gentle magnetic stirring (100 rpm) for 24 h. This process was carried out, separately, 170 
in PBS at pH 7.4, 6.6 and 5.4. At specific time intervals, an aliquot of 2 ml of the external 171 
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medium was withdrawn and filtered through a 0.45-µm membrane. Thereafter, equal volume of 172 
fresh buffer was added to maintain the sink conditions and constant volume. The release of the 173 
free drug was also investigated in the same way. The released amount of DOX in each scheduled 174 
time was estimated by the RP-LC method described in the previous section (section 2.5), using 175 
analytical curves obtained with the release medium (PBS at pH 7.4, 6.6 or 5.4) as diluents. The 176 
cumulative release percentage (CR%) of DOX was determined from the following equation (Eq. 177 
(1)): 178 
𝐶𝑅% = (𝑀𝑡 𝑀𝑖⁄ ) 100         (1) 179 
where Mt and Mi are the amount of drug released at the time t and the initial amount of drug 180 
encapsulated in the NPs, respectively. The in vitro release studies were carried out in triplicate. 181 
For understanding the pH-sensitivity behavior of NPs, swelling studies were performed 182 
by soaking lyophilized NPs into PBS pH 7.4, 6.6 and 5.4 at room temperature and under gentle 183 
shake. Hydrodynamic diameter was measured after 3 h incubation. 184 
2.7. Mathematical modeling of drug release profiles 185 
Monoexponential (Eq. (2)) and biexponential (Eq. (3)) mathematical models as well as the 186 
Korsmeyer-Peppas model (Eq. (4)) were used to analyze DOX in vitro release profile 187 
(MicroMath® Scientist version 2.01, USA). The model that best fit the drug release profile was 188 
selected according to the model selection criteria (MSC), correlation coefficient (r), and 189 
graphical adjustment. The release kinetic rate constants are k (for monoexponential), k1 and k2 190 
(for biexponential). C0, a and b are the initial concentration for mono- and biexponential models, 191 
respectively [32,33]. Finally, the DOX release mechanism was investigated by fitting 60% of 192 
the initial amount of drug released from CS-NPs to the Korsmeyer-Peppas model. In its 193 
corresponding equation, n is the exponent that characterizes the release mechanism and a is a 194 
constant comprising the structural and geometric characteristics of the carrier [34-36]. 195 
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𝐶 = 𝐶0𝑒
−𝑘𝑡           (2) 196 
𝐶 = 𝑎 𝑒−𝑘1𝑡 + 𝑏 𝑒−𝑘2𝑡          (3) 197 
𝑓𝑡 =  𝑎 𝑡𝑛            (4) 198 
2.8. Lyophilization of nanoparticles 199 
NP suspensions DOX-CS-NPs, PEG-DOX-CS-NPs and Polox-DOX-CS-NPs were subjected to 200 
the lyophilization process to obtain dried formulations (L-DOX-CS-NPs, L-PEG-DOX-CS-NPs 201 
and L-Polox-DOX-CS-NPs, respectively). To avoid possible particle aggregation, glycerol 202 
(10%, w/v), mannitol (1%, w/v) and lactose (1, 5 and 10%, w/v) were tested for their 203 
cryoprotectant efficiency. Cryoprotectants were dissolved in the entire volume of NPs under 204 
magnetic stirring for 20 min. Then, these mixtures were frozen at -20°C for 48 h. The water was 205 
removed from frozen NPs by sublimation under vacuum for 48 h using a bench top lyophilizer 206 
(Liotop L101, Liobras, São Carlos, Brazil). As required, lyophilized products were redispersed 207 
with ultra-pure water by magnetic stirring for 10 min. The macroscopic appearance, 208 
physicochemical properties and EE% were evaluated. 209 
2.9. Fourier Transform Infrared Spectroscopy (FT-IR) analysis 210 
In order to investigate the interactions between the drug and NP matrix, FT-IR spectra of dried 211 
NPs, pure DOX, CS and 77KS raw materials were recorded using compressed KBr disk method 212 
with a FT-IR spectrophotometer (Bruker Tensor 27, Bruker Optik, Ettlingen, Germany). 213 
Spectral acquisition was carried out from 4000 to 400 cm-1 range. 214 
2.10. Stability studies of nanoparticles 215 
NP suspensions (DOX-CS-NPs, PEG-DOX-CS-NPs and Polox-DOX-CS-NPs) and the 216 
lyophilized formulations (L-DOX-CS-NPs and L-PEG-DOX-CS-NPs) were studied for their 217 
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stability in low temperature (2 – 8°C). Experiments were conducted over 8 weeks. Lyophilized 218 
samples were first placed inside a desiccator containing silica and then exposed to low 219 
temperature whilst protected from light. Analyses were carried out on the first day of the study, 220 
and subsequently after 2, 4 and 8 weeks. In each time point, all samples were evaluated for 221 
particle size, PDI, ZP and drug content (total drug amount (%) in regard to freshly prepared 222 
formulations). 223 
Additionally, photostability studies were carried out to assess whether suspensions 224 
and/or lyophilized formulations were able to protect the drug after exposure to UVA radiation. 225 
An aliquot of DOX solution or DOX-loaded NPs was put separately into transparent capped 226 
cuvettes (Brand®, UV-Cuvettes micro) and placed into a mirrored chamber with approximately 227 
1,350 W h/m2 incident UVA radiation [37]. On the other hand, an amount of the lyophilized 228 
formulations were weighed and well distributed in Petri dishes. The drug concentration was 229 
measured in different schedule times (0, 2, 8, 24 and 48 h) by the validated RP-LC method. 230 
Zero, first and second order graphics were delineated and the one with the best fit was 231 
considered to establish the kinetic order. 232 
2.11. Cytotoxicity assays  233 
The in vitro antitumor activity of unloaded-CS-NPs, DOX-loaded CS-NPs and free DOX was 234 
determined against HeLa cell line (human epithelial cervical cancer), which was cultured in 235 
DMEM medium (4.5 g/l glucose) supplemented with 10% (v/v) FBS, at 37ºC in a 5% CO2 236 
atmosphere. HeLa cells were seeded into 96-well cell culture plates at a density of 7.5 x 104 237 
cells/ml. Cells were incubated for 24 h under 5% CO2 at 37ºC and afterwards, the medium was 238 
replaced with 100 µl of fresh medium containing the treatments. Free DOX as well as DOX-239 
loaded CS-NPs were assayed at 1 and 10 μg/ml DOX concentration, while unloaded CS-NPs 240 
were assessed at 50 and 200 μg/ml. Following 24 h incubation, the medium was removed and 241 
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100 µl of MTT in PBS (5 mg/ml) diluted 1:10 in medium without FBS was added to the cells 242 
and incubated for 3 h. Finally, the MTT containing medium was removed and 100 µl of DMSO 243 
was added to each well in order to dissolve the purple formazan product. After shaking, the 244 
absorbance of the resulting solution was measured using a SpectraMax M2 (Molecular Devices, 245 
Sunnyvale, CA, USA) microplate reader at 550 nm. Cell viability was calculated as the 246 
percentage of tetrazolium salt reduced by viable cells in each sample. The untreated cell control 247 
(cells with medium only) was taken as 100% viability. 248 
2.12. Statistical analyses 249 
Results are expressed as mean ± standard error (SE) or mean ± standard deviation (SD) of three 250 
independent experiments, and statistical analyses were performed using one-way analysis of 251 
variance (ANOVA) to determine the differences between the datasets, followed by Tukey’s 252 
post-hoc test for multiple comparisons, using SPSS® software (SPSS Inc., Chicago, IL, USA). 253 
p < 0.05 and p < 0.01 indicated significant and highly significant differences, respectively.  254 
3. Results and discussion 255 
In this study, NPs encapsulating DOX were prepared by combination of the standard ionotropic 256 
gelation method [30] and the inclusion of procedures deliberated by our research group. 257 
Therefore, novel pH-responsive CS-NPs were obtained using a mild and solvent-free process 258 
for efficient drug loading [38]. CS is widely regarded as being a non-toxic and biologically 259 
compatible polymer, with great medical potential [39]. Once dissolved in acetic acid aqueous 260 
solution, the amino groups of CS are protonated (NH3
+) and available to interact with the 261 
negatively charged TPP (P3O10
5-) to spontaneously form the NPs [40,41]. With the aim to find 262 
the suitable CS:TPP ratio (w/w), different TPP concentrations were tested since the size and 263 
PDI of NPs depended on the amount of TPP in the formulation. The first condition tested was 264 
CS:TPP (5:1, w/w), but the ratio CS:TPP (5:2, w/w) was chose since it presented the smallest 265 
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size and PDI value. This behavior can be attributed to the greater interaction of CS positive 266 
charges with increasing amount of negative charges of the polyanion TPP [42]. These results 267 
are in agreement with the study reported by Gan et al. [43], in which a linear decrease of size 268 
with decreasing CS to TPP weight ratio was observed. Furthermore, it is worth pointing out that 269 
by increasing the amount of negative charges into the formulation matrix, the free positive 270 
charges of CS were reduced. This lower protonation diminishes the repulsion between CS and 271 
DOX (also positively charged), which, in turn, increases the drug encapsulation efficiency.  272 
The surfactant 77KS was selected as a bioactive adjuvant in the NP formulation based 273 
on previous studies, which showed its pH-sensitive activity along with improved kinetics in the 274 
endosomal pH range and low cytotoxic potential [12,13]. Moreover, it was already 275 
demonstrated that the inclusion of another amphiphile from the same family (77KL, with lithium 276 
counterion) in the composition of polymeric NPs improved their in vitro antitumor activity and 277 
also gave them a pH-responsive behavior [44]. The surfactant 77KS was included into the NPs 278 
at a concentration below its CMC, indicating that it is present in the formulations in the 279 
monomer form. Different concentrations of the surfactant were tested, ranging from 280 
CS:TPP:77KS 5:2:0.1 to 5:2:1 (w/w/w), with 0.1 increase amount of 77KS each time. By having 281 
the concentration ratio of 77KS higher than 5:2:0.5, a flocculation of the NPs took place. In 282 
contrast, concentrations between 0.1 and 0.5 provided satisfactory results. Therefore, the ratio 283 
5:2:0.5 (w/w/w) of CS:TPP:77KS was chosen and maintained for all formulations. 284 
The process to prepare the NPs was optimized to be simple and fast. Firstly, positive 285 
charges (DOX and CS) were mixed [5,17] and, a premixed solution of the negatively charged 286 
compounds (TPP and 77KS) was added drop-wise, leading to spontaneous formation of the 287 
colloidal system. It is known that the polyanion TPP has multiple charged functional groups, 288 
which makes it able to interact with both DOX and CS, resulting in shielding and electrostatic 289 
interactions [17]. The pH of CS solution was set at 5.5, in which about 90% of the amino groups 290 
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of CS (pKa = 6.5) are protonated [45]. Likewise, DOX (pKa = 8.2) possess an amino sugar 291 
moiety also protonated at this pH [46], which allowed competitive binding of DOX to the 292 
negatively charged cross-linking agent (TPP) while forming the NPs.  293 
 The PEGylation of nanomaterials was shown not only to diminish clearance of the 294 
loaded drug, but also to provide enhanced tumor targeting ability due to the prolongation of 295 
plasma circulation time [47]. PEGylated DOX-CS-NPs were prepared from CS and PEG joint 296 
solubilization prior to gelation process, where a CS/PEG network is formed by cross-linking 297 
between hydroxyl groups of PEG and amino groups of CS [48]. Likewise, it is known that block 298 
copolymers, such as the poloxamers, are biological response modifiers with potential ability to 299 
modulate drug resistance in MDR cancer cells. Therefore, here poloxamer-modified DOX-CS-300 
NPs were prepared upon the addition of TPP:77KS into CS:Poloxamer:DOX solution [49]. 301 
Different concentrations of poloxamer were tested (0.2%, 0.5% and 1%, w/v), and the 302 
intermediate one (0.5%) was chose with acceptable physicochemical characteristics. It was 303 
previously reported that micelles containing block copolymers at 0.25 and 2% (w/v), in which 304 
DOX is also non-covalently incorporated, exhibited greater efficacy than free DOX in in vitro 305 
and in vivo tumor models [50].  306 
3.1. Characterization and EE% of nanoparticles 307 
Following the preparation procedure, the stability of the drug after its encapsulation was 308 
assessed through the spectral analysis, as shown in Fig. 2. The UV-Vis spectrum of the drug 309 
extracted from NPs was similar to that obtained for DOX in free solution, which proved the 310 
integrity of DOX molecule after its entrapment into the NP matrix. Moreover, as summarized 311 
in Table 1, DOX-loaded and unloaded NPs were characterized for particle size, PDI, ZP and 312 
pH. The average particle size analysis is a common characterization method, which allows the 313 
understanding of their dispersion and aggregation, as well as helping to predict their possible 314 
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biodistribution. The size of unloaded NPs was in the range of 170 to 211 nm. Increasing 315 
diameters were noticed when DOX was added, indicating the retention of the drug. Likewise, 316 
the mean diameter of PEGylated NPs increased with respect to unmodified NPs, which is a good 317 
indicator of PEG incorporation into the NP structure [22]. Here, it can be stated that PEG was 318 
incorporated into the colloidal gel system via hydrogen bonding between the oxygen atom of 319 
PEG and amino groups of CS. This interaction is weak, which makes the structure of the 320 
PEGylated NPs looser and, consequently, increases their mean diameter [20]. Conversely, 321 
poloxamer-modified NPs presented smaller mean diameter than those PEG-modified NPs. This 322 
is due to the stabilizer power of poloxamer, fact that leads to a rigid arrangement of particles 323 
with less water uptake [49]. Additionally, all CS-based NPs formed systems with narrow size 324 
distribution with PDI values lower than 0.24. The ZP values of the NPs in the range of 21 to 25 325 
mV indicate a positively charged surface owing to the cationic amino groups of CS. Likewise, 326 
when DOX was present, the electric charge remained positive and no considerable changes were 327 
noted.  328 
DOX-loaded NPs displayed high EE% and the mean values obtained for all formulations 329 
were constantly around 65%. These results are in agreement with those found elsewhere [22,51], 330 
and allow us to state that the drug was entrapped into the polymeric network regardless of 331 
modifications made in NPs. Indeed, different amounts of drug loading were tested and discussed 332 
based on EE% capacity. By increasing DOX concentration from 80 to 154 µg/ml, the DOX 333 
EE% decreased from 66.50% ± 2.68 to 51.09% ± 2.88. Similar results were found elsewhere 334 
[17,18,52], pointing out that a larger amount of drug does not mean any increase in 335 
encapsulation efficiency. As a limited number of functional groups is available for electrostatic 336 
interactions with the drug in the NP matrix, the increase in the amount of drug added to the 337 
formulation could have resulted in a decrease in drug entrapment efficiency. Finally, it is worthy 338 
mentioning that NPs without 77KS showed the highest mean EE% value. This behavior could 339 
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be attributed to the assembling of a consistent CS/TPP network with greater amount of TPP 340 
molecules and, thus, of remaining negative charges that allow DOX association. When 77KS 341 
(with only one negatively charged group) binds to CS, no free negative charge remains available 342 
to interact with DOX, therefore leading to diminished EE%. However, it is important to 343 
highlight that when 77KS was incorporated, we achieved higher EE% values than previous 344 
studies that reported DOX EE% values in the order of 47% for PLGA NPs and 20% for CS-345 
based NPs [5,53]. 346 
3.2. In vitro DOX release 347 
Taking advantage of the acidic pHe (6.5 – 7.2) found in the tumor environment compared to the 348 
normal tissues [11,54], pH-sensitive NPs have been developed to achieve accelerated drug 349 
release at the tumor site. In this context, the in vitro drug release profiles of DOX-CS-NPs, PEG-350 
DOX-CS-NPs and Polox-DOX-CS-NPs were studied in PBS buffer mediums at pH 7.4, 6.6 and 351 
5.4 at 37 ± 2°C (Fig. 3). 352 
When 77KS was first studied, it demonstrated pH-dependent membrane-lytic activity on 353 
hemolysis assay, with significant increase at pH 5.4; although with no pharmaceutical 354 
applications up to this time [13]. Here, this surfactant was incorporated into DOX-loaded CS-355 
based NPs and, as can be seen in Fig. 3A, it was clearly demonstrated that the pH-dependent 356 
release pattern of these nanostructures was as evident as was for CS-NPs without 77KS (Fig. 357 
3D). In acidic environment, the release rate was accelerated; with 97 and 100% of DOX released 358 
at pH 6.6 and 5.4 after 6 h, respectively, while only 71% of drug release was reached at pH 7.4. 359 
The cumulative release amount of DOX at pH 6.6 and 5.4 was in general significantly faster (p 360 
< 0.05) than at pH 7.4. A control experiment using free DOX was also carried out under similar 361 
conditions and almost total drug release was reached after 6 h. 362 
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The release of PEG-DOX-CS-NPs was also studied at different pH values, wherein at 363 
acidic conditions the release was noticeably accelerated with 100% of the DOX available in 364 
both pH 6.6 and 5.4 mediums after only 4 h (Fig. 3B). These results demonstrate that PEG did 365 
not inhibit drug release at acidic conditions, which is particularly important in order to maintain 366 
the improved drug delivery in the tumor microenvironment and intracellular compartments. 367 
Unexpectedly, DOX release from PEGylated NPs was not delayed at physiological pH in 368 
comparison with those NPs without PEG (~75 and 76% DOX released at 24 h, respectively). 369 
This behavior appears to be attributed to the formation of a semi-interpenetrating network 370 
between CS and PEG [48] and not to the assembly of a PEG shell around the NPs. 371 
Among the three formulations, Polox-DOX-CS-NPs was the one that presented faster 372 
release rate: release amount of DOX reached 100% after 3 h, 5 h and 8 h at pH 5.4, 6.6 and 7.4, 373 
respectively (Fig. 3C). This behavior may be explained by the hydrophilic pattern of poloxamer 374 
that consequently forms a porous structure in the surface of the DOX-CS-NPs [55]. Poloxamers 375 
are reported to be pore-forming agents and drug-releasing enhancers [56], which corroborated 376 
our results. At this point there is no significant difference among the release rates at each pH (p 377 
> 0.05), which may be justified by the faster release achieved at physiological conditions. 378 
The release mechanisms from CS-based NPs have been reported to be desorption of the 379 
drug from the surface, diffusion of the drug through pores, and degradation of the polymeric 380 
matrix [43]. In the swelling experiments, a considerable increase of particle size was noticed 381 
with a decrease of the buffer pH from 7.4 and 6.6 to 5.4 (178.9 nm, 173.6 nm and 309.7 nm, 382 
respectively). At lower pH value, the protonation of the amino groups of CS is promoted, 383 
leading to an increase of electric density and repulsion force between cross-linked CS chains 384 
[57]. This mechanism allows the medium to penetrate into the nanoparticulate system, 385 
consequently increasing the mean hydrodynamic size [58]. This pH-sensitive swelling behavior, 386 
in turn, could be one of the mechanisms underlying the faster diffusion of DOX from NPs, 387 
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especially in acidic environments with pH as low as 5.4. On the other hand, the lack of swelling 388 
at pH 6.6 is probably attributed to the diminishing CS protonation in this condition, suggesting 389 
that the repulsion forces are not enough to induce NP swelling and, thus, other mechanisms are 390 
involved in the accelerated drug release.  391 
It is worth mentioning that besides the swelling mechanism of CS, DOX may have an 392 
improved solubility and, TPP, a reduced ionization in acidic environments [17,57]. This later 393 
condition may result in NP network destabilization and thus faster drug delivery, which could 394 
be the basis for the pH-responsive drug release observed for the NPs without 77KS (Fig. 3D). 395 
Considering that either CS-NPs with or without 77KS displayed a pH-dependent release 396 
behavior, it can be evidenced that the pH-responsive nature of CS itself appears to play the 397 
dominant role. However, 77KS appears to delay the release at pH 7.4, which is quite important 398 
in order to achieve a target drug release at the tumor site. Therefore, it can be stated that 77KS 399 
has a synergic effect with CS to give to the NPs the pH-responsive behavior. Moreover, it is 400 
noteworthy that another study performed by our research group evidenced that only the NPs 401 
incorporating 77KS showed pH-sensitive membrane-lytic activity (unpublished data), which 402 
also proves the important role of 77KS to improve the pH-sensitivity of the NPs. The ionization 403 
of 77KS is expected to be reduced in an acidic environment [13], which in turn would also 404 
contribute for the destabilization of the NP structure due to the reduced amount of available 405 
anionic charges that interact electrostatically with CS. This process would retain the drug at 406 
physiological conditions and facilitate the drug release as the pH decreases to 6.6 and 5.4.  407 
The increased release at pH 6.6 and 5.4 shows that drug delivery appears to be triggered 408 
at tumor extracellular pHe, as well as at the acidic environment of endosomes. Moreover, the 409 
low DOX release at normal physiological conditions may reduce the side effects that can occur 410 
during cancer treatment. Altogether, these results support the idea that these nanocarriers are a 411 
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potential design to be used as a pH-sensitive system to improve the drug availability on tumor 412 
microenvironment and intracellular compartments.  413 
3.3. Mathematical modeling 414 
The data obtained from in vitro release studies were used to calculate values of release constants 415 
and release exponents with the aim to help understanding the mathematics of release profiles 416 
(Table 2). According to the values of the correlation coefficients (r) and MSC, the data for all 417 
NPs suspensions at pH 7.4 fit better to the biexponential equation (r > 0.99). At this condition, 418 
the DOX release showed an initial burst release (k1), continued by a steady-state release (k2). 419 
These two phases can be explained by the initial drug release from NP surface (drug adsorbed 420 
or entrapped in surface layer), followed by buffer penetration into NPs and drug diffusion 421 
through the swollen rubbery matrix [58]. Moreover, according to the results for a and b 422 
parameters, approximately 68% of the drug was in Polox-DOX-CS-NPs and only 31% was 423 
superficially adsorbed on this nanostructure. Conversely, PEG-DOX-CS-NPs and DOX-CS-424 
NPs had about 25% encapsulated and 75% adsorbed on NP surface. When the mathematical 425 
modeling was performed for pH 6.6 and 5.4, a good fit was observed using the monoexponential 426 
model, with constant rates (k) in the following ranking order: PEG-DOX-CS-NPs > Polox-427 
DOX-CS-NPs > DOX-CS-NPs. 428 
 In the Korsmeyer-Peppas model, high correlation coefficient was obtained (r > 0.99 for 429 
NPs and r > 0.98 for free DOX). The values of release exponent (n) between 0.43 and 0.85 for 430 
DOX-CS-NPs (release medium at pH 7.4, 6.6 and 5.4, with n = 0.6836, 0.4608 and 0.5235, 431 
respectively) indicate a non-Fickian-type release mechanism, i.e., the phenomena responsible 432 
for the DOX release are drug diffusion process from the NPs coupled to relaxation of the 433 
polymeric chains [59]. A non-Fickian model also was found for PEG-DOX-CS-NPs at pH 7.4 434 
(n = 0.5010) and Polox-DOX-CS-NPs at pH 7.4 and pH 5.4 (n = 0.4836 and 0.6638, 435 
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respectively). The same mechanism transport was identified for the release of rivastigmine from 436 
CS-based nanoparticles for brain targeting [60]. When the release data of PEG-DOX-CS-NPs 437 
at pH 6.6 and 5.4 mediums were analyzed, n < 0.43 was obtained and, therefore, the release 438 
mechanism was Fickian, suggesting that the release is a consequential effect of only DOX 439 
amount diffused from the nanostructure. The same occurred for Polox-DOX-CS-NPs at pH 6.6. 440 
Fickian release mechanism was also presented to an anticancer drug loaded into CS-NPs [57]. 441 
Finally, n = 0.2276 was obtained for non-encapsulated DOX, indicating that its release profile 442 
is diffusion-controlled. Altogether, our results demonstrated the remarkable contribution of the 443 
relaxational process of the polymeric matrix for DOX release at pH 7.4, which may justify the 444 
slower drug release under physiological conditions. 445 
3.4. Lyophilization of nanoparticles 446 
Nanoparticulate systems for drug delivery have been subjected to lyophilization in order to 447 
overcome their instabilities [61]. Herein, NP suspensions were lyophilized by freeze drying with 448 
lactose, mannitol or glycerol as cryoprotectants, which are important adjuvants with the ability 449 
to protect NP suspensions from the stresses generated during the lyophilization process, i.e. 450 
freezing and desiccation [62]. When mannitol and glycerol were tested as protectants, the 451 
obtained result was not satisfactory since the redispersion procedure showed a strong tendency 452 
to form aggregates. For the sake of choosing between 1, 5 and 10% lactose, the major criteria 453 
evaluated were the yield, drug content and redispersibility index (ratio between the size after 454 
lyophilization and before lyophilization). Satisfactory values were achieved for 10% lactose 455 
(~92%, ~93% and 1.10, respectively). Moreover, only 10% lactose was able to produce a clear 456 
suspension, without any visible precipitates (Table 1). Sugars are suitable protective agents, 457 
acting by hydrogen bonding and maintaining the solute in a pseudo hydrated state during the 458 
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dehydration step, which thus protects the NP structure from damage in dehydration and 459 
rehydration process [63].  460 
3.5. FT-IR analysis 461 
FT-IR analyses were performed in order to support the CS:TPP cross-link as proof of NP 462 
formation, as well as to confirm the grafting of 77KS, PEG and poloxamer on the surface of 463 
NPs (Fig. 4 and 5). Fig. 4B represents the FT-IR spectrum of CS. The characteristic absorption 464 
peak at 3384 cm-1, representing the presence of OH- groups, indicates that CS is partially 465 
deacetylated. [64]. Peaks at 2850 to 2920 cm-1 show the stretching band of methylene in CS 466 
structure. Moreover, for CS-NPs (Fig. 4C; 5B, C and D), the amino band is shifted from 1652.5 467 
to ~1570 cm-1, confirming that amino groups of CS were involved in the cross-linking by 468 
phosphate (TPP) [49]. This shifting was confirmed by analyzing the spectrum of unloaded CS-469 
NPs (data not showed). Another peak that can be observed in CS-NPs spectra (Fig. 4C; 5B, C 470 
and D) is at 1202 cm-1, corresponding to P=O stretching of the TPP [64]. Pure DOX spectrum 471 
(Fig. 4A) shows peaks at 2933 (C-H), 1730 (C-O), 1617 and 1582 (N-H), 1413 (C-C) and 1072 472 
cm-1 (C-O). In DOX-CS-NPs spectra (Fig. 4C; 5B, C and D), these peaks are also presented as 473 
shifted to 2900 (C-H), 1642 and 1572 (N-H), 1415(C-C) and 1031 cm-1 (C-O). Thus, these 474 
results indicate that DOX was loaded into CS-NPs [18]. Absorption peaks associated to PEG 475 
can be seen at 784 and 897 cm-1, suggesting that PEG grafting was successfully achieved in 476 
PEG-DOX-CS-NPs (Fig. 5D) [21]. Likewise, for Polox-DOX-CS-NPs (Fig. 4C), a stretching 477 
band from 2860 to 2950 cm-1 confirms the incorporation of poloxamer 188. The same strong 478 
peak appears for pure poloxamer, which represents the stretching vibrational band of methylene 479 
group [49,65]. Finally, for 77KS, two strong bands at 1550 cm-1 and 1414 cm-1 represents the 480 
carboxylate ion present in the molecule (Fig. 5A) [66]. The peak at ~1414 cm-1 remains as a 481 
strong band and evidences the incorporation of 77KS in CS-NPs (Fig. 5B and D). For DOX-482 
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CS-NPs without 77KS, this band was shifted to 1423 cm-1 and appears with small intensity (Fig. 483 
5C). The band at 1550 cm-1 could not be used to evidence the incorporation of 77KS because it 484 
overlaps with N-H bending vibrations of CS amino groups. 485 
3.6. Stability studies of nanoparticles 486 
NP suspensions and NPs after lyophilization were submitted to stability studies for a storage 487 
period of 8 weeks at 2 – 8°C.  Particle size, PDI, ZP and drug content were evaluated in each 488 
scheduled time. After two weeks storage, all samples presented a tendency to aggregate. The 489 
parameters evaluated that prove this fact are particle size (> 600 nm) and PDI (> 0.3), suggesting 490 
an increase in the number of larger particles and a decrease in the narrow size distribution of the 491 
suspension. These results were not unexpected, as it was previously reported that CS 492 
microparticles showed reduced ZP and enhanced particle size after 28 days storage [67]. Factors 493 
to explain the size evolution during time storage are swelling, particle aggregation and 494 
interaction of free polymer chains with the particle network [63]. On the other hand, NP 495 
suspensions presented no considerable variations for drug content, which remained around 99% 496 
during storage time. However, the lyophilized NPs displayed a slight decrease in the drug 497 
content after 1-month storage. Altogether, the results obtained in these preliminary studies 498 
indicated that further studies must be conducted in this field in order to improve the stability of 499 
the design formulations.  500 
With the aim to study the ability of the nanosystems to protect the encapsulated drug 501 
from photodegradation, DOX water solution, as well as DOX-CS-NPs and PEG-DOX-CS-NPs 502 
in both suspension and lyophilized states were exposed to UVA radiation. DOX water solution 503 
followed a first kinetic order (r = 0.9857), with half-live (t1/2) = 9.15 h. Likewise, the degradation 504 
profiles of DOX into DOX-CS-NPs and PEG-DOX-CS-NPs were according to a first (r = 505 
0.9374) and second kinetic order (r = 0.9818), with t1/2 = 4.17 h and 5.57 h, respectively. These 506 
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findings of t1/2, therefore, revealed that the nanostructured systems were not able to protect DOX 507 
from the UVA radiation during the entire study period. In contrast, the lyophilized samples L-508 
DOX-CS-NPs and L-PEG-DOX-CS-NPs followed a second kinetic degradation order (r = 509 
0.9975 and 0.9950, respectively) and presented encouraging results about t1/2. L-DOX-CS-NPs 510 
and L-PEG-DOX-CS-NPs demonstrated t1/2 values 15- and 7.5-fold greater (62.5 h and 41.67 h) 511 
compared to their suspension forms, respectively, suggesting an improvement on photostability 512 
of dry solid forms. 513 
3.7. Cytotoxicity assays 514 
In vitro assays are very attractive due to ethical aspects and for being a rapid and effective 515 
pathway to assess toxicological responses of new nanotechnologies before going to in vivo 516 
studies. Therefore, here we performed a preliminary study on the potential antitumor activity of 517 
the pH-responsive DOX-loaded NPs using an in vitro cell model. The cytotoxic responses of 518 
unloaded CS-NPs, DOX-loaded CS-NPs and free DOX were evaluated against HeLa tumor 519 
cells using MTT viability assay. A dose-dependent effect for all formulations tested can be seen 520 
in Fig. 6. The results obtained with DOX-loaded NPs were compared to those with free DOX 521 
in order to ensure that the drug encapsulation improves or at least maintains the cytotoxic effects 522 
of DOX. The in vitro antitumor activity of modified and unmodified DOX-loaded NPs was 523 
generally higher than that of free DOX at both tested concentrations. Finally, the cell viability 524 
was higher than 85% at both tested concentrations of unloaded CS-NPs, indicating that the 525 
surfactant 77KS did not promote significant cytotoxic effects [12]. 526 
4. Conclusions 527 
In this work, we prepared and characterized PEGylated and poloxamer-modified DOX-CS-NPs 528 
incorporating the pH-sensitive lysine-based surfactant 77KS. NPs showed nanoscale size with 529 
relatively high EE%, whereas an improvement on DOX photostability was noticed when NPs 530 
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were into dry solid forms. All formulations displayed pH-triggered DOX release and can be 531 
stated as switching nanodevices in release kinetics, ranging from slow drug delivery while 532 
circulating (pH 7.4) to rapid release kinetics once target sites have been reached (pH 6.6 to 5.4). 533 
Finally, cytotoxicity experiments showed the ability of DOX-loaded CS-NPs to kill HeLa tumor 534 
cells. However, further studies in MDR cancer cells are needed to enhance our knowledge 535 
regarding the role of poloxamer together with 77KS in the sensitization of tumor cells. 536 
Altogether, our findings suggested that the pH-responsive DOX-loaded CS-NPs developed here 537 
could be potential stimulus-responsive drug delivery systems to target cancer cells by triggering 538 
the acidic tumor microenvironment as well as endosomal compartments.  539 
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Figure captions: 689 
Fig. 1. Design of pH-responsive DOX-loaded CS-NPs to facilitate target drug release at the 690 
tumor site.  691 
Fig. 2. UV-Vis absorption spectra of the DOX extracted from NPs (A) and DOX aqueous 692 
solution (B). 693 
Fig.  3. pH-dependent in vitro cumulative DOX release from NPs in PBS buffer at pH 7.4, 6.6 694 
and 5.4. (A) DOX-CS-NPs, (B) PEG-DOX-CS-NPs, (C) Polox-DOX-CS-NPs and (D) DOX-695 
CS-NPs without 77KS. Results are expressed as the mean ± SE of three independent 696 
experiments. Statistical analyses were performed using ANOVA followed by Tukey’s multiple 697 
comparison test. a Significant difference from PBS pH 7.4 (p < 0.05), b highly significant 698 
difference from PBS pH 7.4 (p < 0.01). 699 
Fig. 4. FT-IR spectra of pure DOX (A), CS raw material (B), Polox-DOX-CS-NPS (C) and 700 
Poloxamer 188 (D). 701 
Fig. 5. FT-IR spectra of 77KS (A), DOX-CS-NPs (B), DOX-CS-NPs without 77KS (C) and 702 
PEG-DOX-CS-NPs (D). 703 
Fig. 6. In vitro antitumor activity of unloaded-CS-NPs, free DOX and DOX-loaded CS-NPs in 704 
HeLa cell line. 705 
  706 
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Table 1. Characterization of unloaded and DOX-loaded CS-NPs with or without 77KS. The 707 
lyophilized NPs (L-NPs) were analyzed after redispersion in ultra-pure water.   708 
 709 
  710 
Sample 
Particle size 
(nm) ± SD* 
Polydispersity 
index ± SD* 
Zeta potential 
(mV) ± SD* 
pH EE% ± SD* 
CS-NPs (CS:TPP) 170.30 ± 0.84 0.19 ± 0.02 25.20 ± 1.87 5.66 - 
DOX-CS-NPs (CS:TPP) 190.35 ± 1.70 0.22 ± 0.01 21.90 ± 1.12 5.70 75.54 ± 4.98  
CS-NPs 176.77 ± 1.79 0.20 ± 0.02 24.00 ± 1.82 5.66 - 
DOX-CS-NPs 197.50 ± 2.30 0.22 ± 0.01 21.70 ± 0.81 5.72 66.50 ± 2.68 
PEG-CS-NPs 211.10 ± 1.55 0.24 ± 0.01 23.30 ± 1.96 4.68 - 
PEG-DOX-CS-NPs 226.40 ± 2.33 0.23 ± 0.01 23.65 ± 1.06 5.19 66.32 ± 3.54  
Polox-CS-NPs 184.50 ± 2.00 0.21 ± 0.02 22.05 ± 0.91 5.48 - 
Polox-DOX-CS-NPs 209.70 ± 1.35 0.22 ± 0.03 21.00 ± 0.85 5.60 62.21 ± 2.88  
L-DOX-CS-NPs 217.45 ± 4.49 0.33 ± 0.02 12.40 ± 0.15 6.14 67.42 ± 10.85 
L-PEG-DOX-CS-NPs 491.60 ± 32.38 0.73 ± 0.09 20.45 ± 0.78 5.91 65.32 ± 3.18 
L-Polox-DOX-CS-NPs 252.80 ± 7.46 0.40 ± 0.03 17.50 ± 0.93 5.98 61.27 ± 2.28 
31 
 
Table 2. Observed rate constants, correlation coefficients, MSC and half-lives (t1/2) obtained by 711 
mathematical modeling of DOX release from the different NPs when immersed in PBS buffer at 712 
pH 7.4, 6.6 and 5.4. Results are expressed as mean ± standard deviation (SD) of three 713 
experiments. 714 
 715 
  716 
 
pH 
medium 
DOX-CS-NPs PEG-DOX-CS-NPs Polox-DOX-CS-NPs 
Biexponential 
7.4 
   
r 0.99 ± 0.01 1.00 ± 0.01 1.00 ± 0.01 
MSC 3.96 ± 0.36 4.28 ± 0.25 4.17 ± 0.45 
k1 (h
-1) 0.44 ± 0.05 0.67 ± 0.07 2.84 ± 1.25 
t1/2  k1  (h
-1) 1.58 ± 0.47 1.02 ± 0.29 0.24 ± 0.09 
k2 (h
-1) 0.002 ± 0.01 0.01 ± 0.01 0.36 ± 0.36 
t1/2  k2 (h
-1) 407.64 ± 33.76 93.64 ± 9.12 1.91 ± 0.38 
a 0.74 ± 0.04 0.70 ± 0.03 0.31 ± 0.08 
b 0.23 ± 0.04 0.26 ± 0.02 0.68 ± 0.08 
Monoexponential     
r 
6.6 
0.99 ± 0.01 0.99 ± 0.01 0.98 ± 0.01 
MSC 3.74 ± 0.32 3.46 ± 0.63 3.13 ± 0.35 
k (h-1) 0.64 ± 0.04 1.23 ± 0.08 1.05 ± 0.08 
t1/2 (h
-1)  1.07 ± 0.05 0.56 ± 0.03 0.65 ± 0.14 
r 
5.4 
1.00 ± 0.01 0.99 ± 0.01 1.00 ± 0.00 
MSC 4.68 ± 0.29 3.31 ± 0.31 5.07 ± 0.25 
k (h-1) 0.76 ± 0.03 0.98 ± 0.07 0.91 ± 0.03 
t1/2 (h
-1)  0.90 ± 0.10 0.71 ± 0.20 0.76 ± 0.19 
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